非感染性葡萄膜炎管理的经济负担与成本效益：系统综述

数据集获取（Figshare）

• 源站标题：Economic Burden and Cost-Effectiveness of Management of Non-Infectious Uveitis: A Systematic Review
• DOI：10.6084/m9.figshare.28166979.v1
• 发布日期：2025-01-08
• 文件数：3 个
• 文件总体积：70.93 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Economic_Burden_and_Cost-Effectiveness_of_Management_of_Non-Infectious_Uveitis_A_Systematic_Review/28166979

命令行下载

curl -L -o "ioii_a_2450472_sm1431.docx" "https://ndownloader.figshare.com/files/51552066"
curl -L -o "ioii_a_2450472_sm1430.docx" "https://ndownloader.figshare.com/files/51552069"
curl -L -o "ioii_a_2450472_sm1429.docx" "https://ndownloader.figshare.com/files/51552072"

文件清单

• ioii_a_2450472_sm1431.docx（32.86 KB）
• ioii_a_2450472_sm1430.docx（20.66 KB）
• ioii_a_2450472_sm1429.docx（17.42 KB）

文件总体积 70.93 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To evaluate the economic burden and cost-effectiveness of interventions and management of non-infectious uveitis (NIU).
A comprehensive search was conducted across Medline, Embase, and Scopus databases from inception to March 2023. Risk of bias assessments were conducted using the Joanna Briggs Institute critical appraisal tools.
A total of 24 articles consisting of 16 economic burden studies (67%) and 9 cost-effectiveness or cost-utility studies (38%) met the inclusion criteria. Annual direct medical costs ranged from $16,428 to $134,135 USD 2023, with costs being 4.3 times higher for those with blindness compared to those without vision loss. Direct medical costs for corticosteroid, immunosuppressive, and biologic therapies were $19,497, $29.979, and $45,830, respectively. Indirect costs ranged from $806 to $57,170, with costs being 2.1 times higher for persistent NIU and 2.3 times higher for those with blindness. Annual medication and intervention costs ranged from $345 to $13,134, with prescription drug costs being 60% higher for blind patients compared to those with moderate vision loss. Overall, cost-effectiveness analyses show promise for treatments like adalimumab and certain implants, though the extent of economic benefit depends on price reductions and healthcare system variations. Varying parameters like willingness-to-pay (WTP) thresholds and input parameters further complicated comparability.
NIU poses a significant economic impact, particularly in patients with blindness and those on advanced therapies. While evidence is growing in Western countries like the US and UK, further research in non-westernized countries is warranted for a comprehensive, global understanding of the disease’s economic burden.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28166979.v1（source: https://tandf.figshare.com/articles/dataset/Economic_Burden_and_Cost-Effectiveness_of_Management_of_Non-Infectious_Uveitis_A_Systematic_Review/28166979）。